<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Thyroid Nodule Biopsy Outcomes</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            margin: 20px;
            max-width: 800px;
        }
        h1, h2, h3 {
            color: #2c3e50;
        }
        a {
            color: #3498db;
            text-decoration: none;
        }
        a:hover {
            text-decoration: underline;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
        }
        table, th, td {
            border: 1px solid #ddd;
        }
        th, td {
            padding: 8px;
            text-align: center;
        }
        th {
            background-color: #f4f4f4;
        }
    </style>
</head>
<body>
    <h1>What are the possible outcomes of thyroid nodule biopsy?</h1>
    <p>Thyroid nodule biopsy, also known as fine needle aspiration (FNA) biopsy, is a crucial diagnostic tool for evaluating thyroid nodules. The possible outcomes of a thyroid nodule biopsy can be categorized into several groups:</p>

    <h2>Biopsy Results</h2>

    <h3>Benign</h3>
    <p>The majority of thyroid nodule biopsies (approximately 70%) yield benign results (<a href="https://my.clevelandclinic.org/health/diagnostics/thyroid-biopsy">Cleveland Clinic</a>). This indicates that the nodule is non-cancerous and typically requires no further intervention unless it causes symptoms due to its size or growth (<a href="https://www.mountsinai.org/care/ent/surgery/thyroid/thyroid-nodules-diseases/evaluation">Mount Sinai</a>).</p>

    <h3>Malignant</h3>
    <p>About 3% to 7% of thyroid biopsy results are classified as malignant (<a href="https://my.clevelandclinic.org/health/diagnostics/thyroid-biopsy">Cleveland Clinic</a>). This diagnosis confirms the presence of thyroid cancer and usually necessitates surgical intervention.</p>

    <h3>Suspicious</h3>
    <p>When a biopsy result is deemed suspicious, there is a 60% to 75% chance that the nodule is cancerous (<a href="https://my.clevelandclinic.org/health/diagnostics/thyroid-biopsy">Cleveland Clinic</a>). These cases often require additional testing or surgical removal for definitive diagnosis.</p>

    <h3>Atypia of Undetermined Significance (AUS)</h3>
    <p>This category indicates that the nodule has both benign and malignant characteristics. Approximately 5% to 15% of nodules in this category are ultimately found to be cancerous (<a href="https://my.clevelandclinic.org/health/diagnostics/thyroid-biopsy">Cleveland Clinic</a>).</p>

    <h3>Follicular Neoplasm</h3>
    <p>For nodules classified as follicular neoplasms, it is challenging to determine malignancy without surgical removal. About 15% to 30% of these nodules are eventually diagnosed as cancerous (<a href="https://my.clevelandclinic.org/health/diagnostics/thyroid-biopsy">Cleveland Clinic</a>).</p>

    <h3>Non-diagnostic</h3>
    <p>A non-diagnostic result occurs when there are insufficient cells in the sample to make a reliable diagnosis (<a href="https://my.clevelandclinic.org/health/diagnostics/thyroid-biopsy">Cleveland Clinic</a>). This outcome is seen in about 7.2% of cases, and of these, approximately 13.4% are found to be cancerous when surgically removed (<a href="https://www.thyroid.org/patient-thyroid-information/ct-for-patients/february-2023/vol-16-issue-2-p-7-8/">American Thyroid Association</a>).</p>

    <h2>Accuracy and Limitations</h2>
    <p>The overall accuracy of thyroid nodule biopsy is approximately 86% (<a href="https://www.thyroid.org/patient-thyroid-information/ct-for-patients/february-2023/vol-16-issue-2-p-7-8/">American Thyroid Association</a>). However, false-negative results can occur. For nodules 4 cm or larger, the accuracy of FNA biopsy decreases significantly (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2910711/">PMC</a>).</p>

    <h2>Common Molecular Markers for Thyroid Nodule Evaluation</h2>
    <table>
        <thead>
            <tr>
                <th>Molecular Marker</th>
                <th>Sensitivity (%)</th>
                <th>Specificity (%)</th>
                <th>PPV (%)</th>
                <th>NPV (%)</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>ThyGeNEXT</td>
                <td>98</td>
                <td>98</td>
                <td>94</td>
                <td>99</td>
            </tr>
            <tr>
                <td>ThyraMIR</td>
                <td>98</td>
                <td>98</td>
                <td>94</td>
                <td>99</td>
            </tr>
            <tr>
                <td>Afirma GSC</td>
                <td>91</td>
                <td>68</td>
                <td>47</td>
                <td>96</td>
            </tr>
            <tr>
                <td>BRAF Mutation</td>
                <td>85.4</td>
                <td>97.1</td>
                <td>91.4</td>
                <td>95.9</td>
            </tr>
            <tr>
                <td>ThyroSeq</td>
                <td>70</td>
                <td>77</td>
                <td>42</td>
                <td>91</td>
            </tr>
            <tr>
                <td>RAS Mutation</td>
                <td>66</td>
                <td>98.5</td>
                <td>93.5</td>
                <td>82.5</td>
            </tr>
            <tr>
                <td>TERT Promoter Mutation</td>
                <td>7</td>
                <td>100</td>
                <td>7</td>
                <td>97</td>
            </tr>
        </tbody>
    </table>
       <h2>Key Insights</h2>
    <ul>
        <li><strong>ThyGeNEXT/ThyraMIR</strong>: High sensitivity and specificity, often used together for risk stratification.</li>
        <li><strong>Afirma GSC</strong>: Moderate sensitivity and lower specificity but widely utilized for benign risk stratification.</li>
        <li><strong>BRAF Mutation</strong>: Excellent specificity, often used for detecting malignancy.</li>
        <li><strong>ThyroSeq</strong>: Broad molecular panel with reasonable sensitivity and specificity.</li>
        <li><strong>RAS and TERT Promoter Mutations</strong>: Specific but with varied sensitivity, useful for targeted risk assessment.</li>
    </ul>
    <p>These molecular tests are primarily used for indeterminate thyroid nodules (Bethesda III and IV categories) and should be interpreted in conjunction with clinical and ultrasound findings.</p>

    <hr>

    <h2>References for the table</h2>
    <ol>
        <li><a href="https://thygenext-thyramir.com">ThyGeNEXT/ThyraMIR</a></li>
        <li><a href="https://www.endocrinology.org/endocrinologist/132-summer-2019/features/molecular-markers-in-diagnosing-thyroid-cancer">Afirma GSC</a></li>
        <li><a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.746776/full">BRAF Mutation</a></li>
        <li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8345070/">ThyroSeq</a></li>
        <li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8345070/">RAS Mutation</a></li>
        <li><a href="https://erc.bioscientifica.com/view/journals/erc/21/5/825.xml">TERT Promoter Mutation</a></li>
    </ol>
       <h2>Limitations of Molecular Markers</h2>

    <h3>1. Diagnostic Accuracy</h3>
    <ul>
        <li><strong>Sensitivity and Specificity</strong>: Many molecular tests exhibit variable sensitivity and specificity. For example, the Afirma Gene Expression Classifier (GEC) has shown sensitivity ranging from 75% to 100% and specificity from 5% to 53%, while ThyroSeq V2 displays sensitivity from 40% to 100% and specificity from 56% to 93% (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5915469/">PMC</a>).</li>
        <li><strong>Low Positive Predictive Value (PPV)</strong>: The PPV of some markers, such as RAS mutations, has been reported to be as low as 7% to 25%, indicating that a significant proportion of positive results may not correspond to malignancy (<a href="https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.590128/full">Frontiers in Endocrinology</a>).</li>
    </ul>

    <h3>2. Overlap Between Benign and Malignant Conditions</h3>
    <p>Many molecular markers are not exclusive to malignant conditions; they can also be present in benign nodules. This overlap complicates the interpretation of results and may lead to unnecessary surgeries or interventions for benign lesions (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3603017/">PMC</a>, <a href="https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.590128/full">Frontiers in Endocrinology</a>).</p>

    <h3>3. Emerging Pathological Entities</h3>
    <p>The introduction of new histopathological classifications, such as Non-Invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP), has further complicated the landscape. Molecular tests were developed prior to this classification and may misclassify NIFTP as malignant, thereby affecting their diagnostic performance (<a href="https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.590128/full">Frontiers in Endocrinology</a>, <a href="https://pure.johnshopkins.edu/en/publications/preoperative-molecular-markers-in-thyroid-nodules">Johns Hopkins University</a>).</p>

    <h3>4. Sampling Errors</h3>
    <p>The accuracy of molecular testing is inherently limited by the quality of the fine needle aspiration (FNA) samples. Inadequate sampling can lead to non-diagnostic results or misclassification, which diminishes the reliability of molecular diagnostics (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3603017/">PMC</a>, <a href="https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.590128/full">Frontiers in Endocrinology</a>).</p>

    <h3>5. Cost and Accessibility</h3>
    <p>The cost-effectiveness of molecular testing remains a concern, particularly in resource-limited settings. While some studies suggest that these tests can reduce unnecessary surgeries, the actual impact on surgical decision-making has been marginal, with only a small percentage of patients experiencing altered management based on molecular testing results (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5915469/">PMC</a>, <a href="https://pure.johnshopkins.edu/en/publications/preoperative-molecular-markers-in-thyroid-nodules">Johns Hopkins University</a>).</p>

    <h3>6. Lack of Long-term Outcome Data</h3>
    <p>There is insufficient long-term data demonstrating the impact of molecular markers on patient outcomes. Most studies are limited by small sample sizes and single-institution biases, which may not reflect broader clinical practice (<a href="https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.590128/full">Frontiers in Endocrinology</a>, <a href="https://pure.johnshopkins.edu/en/publications/preoperative-molecular-markers-in-thyroid-nodules">Johns Hopkins University</a>).</p>

    <h3>7. Pediatric Considerations</h3>
    <p>Current data do not support the routine use of molecular markers in pediatric patients due to a lack of validation studies in this population, limiting their applicability in younger patients (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5915469/">PMC</a>, <a href="https://pure.johnshopkins.edu/en/publications/preoperative-molecular-markers-in-thyroid-nodules">Johns Hopkins University</a>).</p>

    <p>In summary, while molecular markers can provide valuable information in the evaluation of thyroid nodules, their limitations must be carefully considered when interpreting results and making clinical decisions. A comprehensive approach that includes clinical history, imaging findings, and cytological analysis remains essential in managing indeterminate thyroid nodules effectively.</p>

       <h1>Differences Between ThyroSeq v3 and Latest Afirma GSC Test</h1>
    <p>The salient differences between ThyroSeq v3 and the latest Afirma Gene Sequencing Classifier (GSC) are as follows:</p>

    <h2>1. Test Methodology</h2>
    <ul>
        <li><strong>ThyroSeq v3</strong>: Uses next-generation sequencing to detect both DNA and RNA alterations (<a href="https://academic.oup.com/jcem/article/108/9/e698/7095610?login=false">Journal of Clinical Endocrinology &amp; Metabolism</a>).</li>
        <li><strong>Afirma GSC</strong>: Primarily an RNA-based test (<a href="https://www.thyroid.org/patient-thyroid-information/ct-for-patients/september-2022/vol-15-issue-9-p-5-6/">Thyroid.org</a>).</li>
    </ul>

    <h2>2. Diagnostic Performance</h2>
    <ul>
        <li><strong>Sensitivity</strong>: ThyroSeq v3 (97%) vs. Afirma GSC (100%) (<a href="https://aot.amegroups.org/article/view/7048/html">Annals of Thyroid</a>).</li>
        <li><strong>Specificity</strong>: ThyroSeq v3 (85%) vs. Afirma GSC (80%) (<a href="https://aot.amegroups.org/article/view/7048/html">Annals of Thyroid</a>).</li>
    </ul>

    <h2>3. Cost-Effectiveness</h2>
    <ul>
        <li><strong>ThyroSeq v3</strong>: $14,277 per correct diagnosis (<a href="https://www.thyroseq.com/physicians/test-description/featured-publications/molecular-testing-of-bethesda-iiiiv-thyroid-nodules-a-cost-effectiveness-analysis/">ThyroSeq</a>).</li>
        <li><strong>Afirma GSC</strong>: $17,873 per correct diagnosis (<a href="https://www.thyroseq.com/physicians/test-description/featured-publications/molecular-testing-of-bethesda-iiiiv-thyroid-nodules-a-cost-effectiveness-analysis/">ThyroSeq</a>).</li>
    </ul>

    <h2>4. "Rule-In" and "Rule-Out" Capabilities</h2>
    <ul>
        <li><strong>ThyroSeq v3</strong>: Shows better overall performance (AUC 0.95) and superior "rule-out" ability with a Negative Likelihood Ratio (NLR) of 0.02 (<a href="https://pubmed.ncbi.nlm.nih.gov/34054725/">PubMed</a>).</li>
        <li><strong>Afirma GSC</strong>: Good overall performance (AUC 0.90) but less effective "rule-out" ability compared to ThyroSeq v3 (<a href="https://pubmed.ncbi.nlm.nih.gov/34054725/">PubMed</a>).</li>
    </ul>

    <h2>5. Impact on Clinical Management</h2>
    <p>Both tests demonstrate a similar ability to help avoid unnecessary surgeries, with about 49% of patients avoiding surgery based on benign/negative results (<a href="https://aot.amegroups.org/article/view/7048/html">Annals of Thyroid</a>).</p>

    <h2>6. Preference in Cost-Effectiveness Analysis</h2>
    <p>ThyroSeq v3 was preferred over Afirma GSC in 68.5% of cases during a probabilistic sensitivity analysis (<a href="https://www.thyroseq.com/physicians/test-description/featured-publications/molecular-testing-of-bethesda-iiiiv-thyroid-nodules-a-cost-effectiveness-analysis/">ThyroSeq</a>).</p>

    <hr>

    <h2>Summary</h2>
    <p>While both tests show high sensitivity and improved specificity compared to their previous versions, ThyroSeq v3 appears to have a slight edge in overall performance and cost-effectiveness based on current evidence.</p>

</body>
</html>
